Major symptom score utility index for patients with acute rhinosinusitis

American Journal of Rhinology and Allergy

Volumn 25, Issue 3, 2011, Pages

  Revicki, Dennis A ^a   Margolis, Mary Kay ^a   Thompson, Christine L ^a   Meltzer, Eli O ^b   Sandor, David W ^c,d   Shaw, James W ^e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^c TOURO COLLEGE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; MOMETASONE FUROATE;

ADULT; ALGORITHM; ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR SYMPTOM SCORE; MAJOR SYMPTOM SCORE UTILITY INDEX; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PHYSICIAN GLOBAL IMPROVEMENT SCALE; PSYCHOMETRY; RATING SCALE; RHINOSINUSITIS; SCORING SYSTEM; SINO NASAL OUTCOME TEST; SYMPTOM; VISUAL ANALOG SCALE;

ACUTE DISEASE; ADULT; ALGORITHMS; DISEASE PROGRESSION; FACIAL PAIN; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; MALE; MIDDLE AGED; NASAL OBSTRUCTION; PSYCHOMETRICS; QUESTIONNAIRES; RESEARCH DESIGN; RHINITIS; SEVERITY OF ILLNESS INDEX; SINUSITIS;

EID: 79957511002     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2011.25.3575     Document Type: Article

References (35)

1. Shapiro GG, and Rachelefsky GS. Introduction and definition of sinusitis. J Allergy Clin Immunol Sep 90:417-418, 1992.
2. Lanza DC, and Kennedy DW. Adult rhinosinusitis defined. Otolaryngol Head Neck Surg 117:S1-S7, 1997. (Pubitemid 27435423)
3. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Establishing definitions for clinical research and patient care. J Allergy Clin Immunol 114(suppl):155-212, 2004. (Pubitemid 39575875)
4. Meltzer EO, Charous BL, Busse WW, et al. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. J Allergy Clin Immunol 106:630-637, 2000.
5. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 193:3-5, 2004. (Pubitemid 38623547)
6. Gliklich RE, and Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg 113:104-109, 1995.
7. Agency for Healthcare Research and Quality (AHRQ). Update on acute bacterial rhinosinusitis, summary. Evidence report/technology assessment, No. 124, AHRQ Publication No. 05-E020-2, Agency for Healthcare Research and Quality, Rockville, MD, June 2005.
8. Druce HM. Diagnosis of sinusitis in adults: History, physical examination, nasal cytology, echo, and rhinoscope. J Allergy Clin Immunol 90:436-441, 1992.
9. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Developing guidance for clinical trials. J Allergy Clin Immunol 118(suppl):S17-S61, 2006. (Pubitemid 44648297)
10. Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: A practice parameter update. J Allergy Clin Immunol 116(suppl):S13-S47, 2005. (Pubitemid 41715240)
11. Osguthorpe JD. Adult rhinosinusitis: Diagnosis and management. Am Fam Physician 63:69-76, 2001. (Pubitemid 32096415)
12. Lund V, Black S, Laszlo ZS, et al. Budesonide aqueous nasal spray is effective as monotherapy in stable patients with chronic rhinosinusitis. J Allergy Clin Immunol 109:290-293, 2002.
13. Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol 92:812-823, 1993. (Pubitemid 23361621)
14. Wasserfallen JB, Gold K, Schulman KA, et al. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol 100:16-22, 1997. (Pubitemid 27328526)
15. Meltzer EO, Bachert C, and Staudinger H. Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 116:1289-1295, 2005. (Pubitemid 41740939)
16. Nayak AS, Settipane GA, Pedinoff A, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol 89:271-278, 2002. (Pubitemid 36188026)
17. Wilke CT, Pickard AS, Walton SM, et al. Statistical implications of utility weighted and equally weighted HRQL measures: An empirical study. Health Econ 19:101-110, 2009.
18. Piccirillo JF, Merritt MG Jr, and Richards ML. Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). Otolaryngol Head Neck Surg 126:41-47, 2002. (Pubitemid 41122866)
19. Pynnonen MA, Kim HM, and Terrell JE. Validation of the Sino-Nasal Outcome Test 20 (SNOT-20) domains in nonsurgical patients. Am J Rhinol Allergy 23:40-45, 2009.
20. Jaeschke R, Singer J, and Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10:407-415, 1989.
21. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 47:81-87, 1994. (Pubitemid 24034293)
22. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: The multiattribute Asthma Symptom Utility Index. Chest 114:998-1007, 1998. (Pubitemid 28495893)
23. Lo PS, Tong MC, Revicki DA, et al. Rhinitis Symptom Utility Index (RSUI) in Chinese subjects: A multiattribute patient-preference approach. Qual Life Res 15:877-887, 2006. (Pubitemid 43800759)
24. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res 7:693-702, 1998. (Pubitemid 29089249)
25. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 34:702-722, 1996. (Pubitemid 126433265)
26. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care Feb 40:113-128, 2002.
27. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics 7:503-520, 1995.
28. Hays RD, and Revicki DA. Reliability and validity (including responsiveness). In Assessing Quality of Life in Clinical Trials, 2nd ed. Fayers P, and Hays RD (Eds). New York: Oxford University Press, 25-39, 2005.
29. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Erlbaum, 1988.
30. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61:102-109, 2008.
31. Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 14:285-295, 2005. (Pubitemid 40576381)
32. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 9:887-900, 2000. (Pubitemid 32210183)
33. Neumann PJ, Goldie SJ, and Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health 21:587-611, 2000. (Pubitemid 30480336)
34. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 34:702-722, 1996.
35. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics. 7:503-520, 1995.